Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Debt to Equity (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Debt to Equity for 9 consecutive years, with -$0.06 as the latest value for Q4 2023.

  • Quarterly Debt to Equity fell 122.98% to -$0.06 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$0.06 through Dec 2023, down 122.98% year-over-year, with the annual reading at -$0.06 for FY2023, 122.98% down from the prior year.
  • Debt to Equity for Q4 2023 was -$0.06 at Cartesian Therapeutics, down from $0.37 in the prior quarter.
  • The five-year high for Debt to Equity was $384.79 in Q2 2019, with the low at -$5.97 in Q2 2021.
  • Average Debt to Equity over 5 years is $19.53, with a median of $0.28 recorded in 2022.
  • The sharpest move saw Debt to Equity surged 39198.5% in 2019, then tumbled 425.67% in 2021.
  • Over 5 years, Debt to Equity stood at $2.25 in 2019, then tumbled by 161.16% to -$1.38 in 2020, then surged by 182.66% to $1.14 in 2021, then plummeted by 75.41% to $0.28 in 2022, then crashed by 122.98% to -$0.06 in 2023.
  • According to Business Quant data, Debt to Equity over the past three periods came in at -$0.06, $0.37, and $0.35 for Q4 2023, Q2 2023, and Q1 2023 respectively.